Multiple Myeloma

SRI has significant experience in Multiple Myeloma (MM), conducting extensive qualitative and quantitative research across a variety of topics as well as Big Data Analytics. SRI’s work includes demand estimation and forecasting studies for new indication approvals and product launches, patient and physician segmentation, and multi-wave sales force effectiveness (SFE) studies. SRI has also executed qualitative projects focused on treatment decision drivers, patient journey mapping, and market access challenges.

Our experience extends to analyzing clinical trial insights, commercial development, and planning, including work on CAR-T therapies specific to MM. This comprehensive approach supports strategic planning from early development through lifecycle management, enabling clients to optimize positioning, targeting, and commercialization in the MM therapeutic area.